QGEN News
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Analysts downgraded Qiagen, Alcoa and Dutch Bros, cutting price targets for Qiagen to $52 and Dutch Bros to $46.read more...
Benzinga
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of QIAGEN N.V. (NYSE: QGEN) to the EQT XI fund for 46.50 in cash per share.Halper Sadeh encourages QIAGEN shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free...
Business Wire
QIAGEN reports preliminary Q3 2026 results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full...
Business Wire
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (QIAGEN or the Company) and the EQT XI fund (EQT Private Equity) today announced an agreement under which Crown NL Bidco B.V. (the Bidder) announced its decision to make an all-cash voluntary public takeover offer for the acquisition of all...
Business Wire
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis...
Business Wire
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a...
Business Wire
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
Zacks
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria...
Business Wire